Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide in children with achondroplasia (111-205 extension)
NCT02724228Phase 2Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jan 2016
- Primary completion
- Dec 2027
- Modality
- Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of vosoritide in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical. Started Jan 2016; status: active, not recruiting.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT02724228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724228.